A5035263718- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Nonmelanoma Skin Cancer Studies
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- AI in cancer detection
- Cell Image Analysis Techniques
- Cutaneous lymphoproliferative disorders research
- Organ Transplantation Techniques and Outcomes
- Optical Coherence Tomography Applications
- Computational Drug Discovery Methods
- Clinical Nutrition and Gastroenterology
- Brain Metastases and Treatment
- Breast Cancer Treatment Studies
- Polyomavirus and related diseases
- Advanced Biosensing Techniques and Applications
- Allergic Rhinitis and Sensitization
- Renal Transplantation Outcomes and Treatments
- Liver Disease and Transplantation
- Cell Adhesion Molecules Research
- Organ Donation and Transplantation
- Sarcoma Diagnosis and Treatment
- Infectious Diseases and Mycology
Royal Prince Alfred Hospital
2016-2025
Melanoma Institute Australia
2016-2025
The University of Sydney
2016-2025
The University of Western Australia
2015-2025
Queen's University
1980-2025
Mater Health Services
2013-2024
Mater Misericordiae Hospital
2010-2024
Royal North Shore Hospital
1983-2024
National Health and Medical Research Council
2002-2024
University of Sussex
2021-2024
To revise the staging system for cutaneous melanoma on basis of data from an expanded American Joint Committee Cancer (AJCC) Melanoma Staging Database.The recommendations were made a multivariate analysis 30,946 patients with stages I, II, and III 7,972 stage IV to clarify TNM classifications grouping criteria.Findings new definitions include following: (1) in localized melanoma, tumor thickness, mitotic rate (histologically defined as mitoses/mm(2)), ulceration most dominant prognostic...
PURPOSE: The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer centers cooperative groups contributed staging survival data from a total 30,450 melanoma patients their databases in order to validate this proposal. PATIENTS AND METHODS: There were 17,600 with complete clinical, pathologic, follow-up information. Factors predicting melanoma-specific rates analyzed...
Answer questions and earn CME/CNE To update the melanoma staging system of American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, III diagnosed since 1998. Based analyses this new database, existing seventh edition AJCC stage IV contemporary clinical trial data, Melanoma Expert Panel introduced several important changes to Tumor, Nodes, Metastasis (TNM) classification grouping criteria. Key in eighth...
We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma.
Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in phase 3 trial.
Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., until death from melanoma) among patients node-positive intermediate-thickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node dissection for sentinel-node metastases not clear.
To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma correlate status with clinicopathologic features outcome.Consecutive BRAF-tested Australian patients (n = 197) were observed prospectively. A comprehensive range variables correlated mutation status, a survival analysis was conducted.Forty-eight percent had mutation; 70 (74%) V600E, 19 (20%) V600K, six (6%) other genotypes. Other than age at diagnosis distant metastasis (median age, 56 v 63 years for...
Objective To evaluate the multicenter application of intraoperative lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection (LM/SL/SCLND) for management early-stage melanoma. Summary Background Data The multidisciplinary technique LM/SL/SCLND has been widely adopted, but not validated in a trial. authors began international Multicenter Selective Lymphadenectomy Trial (MSLT) 5 years ago to survival patients with primary melanoma after wide excision alone...
Highlights•Activated T cell signatures/populations drive response to anti-PD-1-based therapies•EOMES+CD69+CD45RO+ effector memory cells are associated with response•EOMES+CD69+CD45RO+ expression is longer PFS and tumor shrinkage•Non-responders TIL-hot tumors express other immune drug targetsSummaryCancer immunotherapies provide survival benefits in responding patients, but many patients fail respond. Identifying the biology of treatment resistance a priority optimize selection improve...
To determine whether density and distribution of tumor-infiltrating lymphocytes (TILs; TIL grade) is an independent predictor sentinel lymph node (SLN) status survival in patients with clinically localized primary cutaneous melanoma.From the Melanoma Institute Australia database, 1,865 a single melanoma ≥ 0.75 mm thickness were identified. The associations clinical pathologic factors SLN status, recurrence-free (RFS), melanoma-specific (MSS) analyzed.The majority had either no (TIL grade 0;...
The objective of this study was to evaluate, in an international multicenter phase III trial, the accuracy, use, and morbidity intraoperative lymphatic mapping sentinel node biopsy (LM/SNB) for staging regional nodal basin patients with early-stage melanoma.Since our introduction LM/SNB 1990, technique has been widely adopted become part American Joint Committee on Cancer (AJCC) system. Eleven years ago, authors began Multicenter Selective Lymphadenectomy Trial (MSLT-I) compare 2 treatment...
To evaluate the effects of treatment with potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune responses to metastatic melanoma in tissues taken before and after treatment.Thirty-seven tumor biopsies were collected from 15 patients unresectable American Joint Committee Cancer stage III IV immediately approximately 7 days commencement inhibitor at time progression. Immunohistochemical staining was carried out using specific antibodies for CD8, CD4, CD20, CD1a, Granzyme...
Multiple BRAF inhibitor resistance mechanisms have been described, however, their relative frequency, clinical correlates, and effect on subsequent therapy not assessed in patients with metastatic melanoma.Fifty-nine BRAF(V600)-mutant melanoma metastases from treated dabrafenib or vemurafenib were analyzed. The genetic profile of tumor signaling pathway activity was correlated clinicopathologic features therapeutic outcomes.Resistance identified 58% progressing tumors alterations common....
The value of elective lymph node dissection (ELND) for melanoma patients with clinically uninvolved regional nodes remains controversial. However, it has been proposed that selective 'sentinel' biopsy reliably identifies individuals micrometastases, who are most likely to benefit from full ELND. aim this study was confirm metastatic cells travelling in lymphatics do not bypass the sentinel node. After preoperative lymphoscintigraphy and intraoperative injection blue dye around primary site,...
The Melanoma Staging Committee of the AJCC has proposed major revisions melanoma TNM and stage grouping criteria. committee members represent most cooperative groups cancer centers worldwide with a special interest in melanoma; also collectively had clinical experience over 40,000 patients. new staging system better reflects independent prognostic factors that are used trials reporting outcomes various treatment modalities. Major include 1) thickness ulceration, but not level invasion, to be...
To analyze prognostic factors, effects of treatment, and survival for patients with cerebral metastases from melanoma.All melanoma treated at the Sydney Melanoma Unit between 1952 2000 were identified. From 1985 to 2000, diagnosed using consistent modern techniques this cohort was analyzed in detail. Multivariate analysis factors performed.A total 1137 identified; 686 2000. For these patients, median time primary diagnosis metastasis 3.1 years (range, 0 41 years). A 646 (94%) have died as a...
Abstract Purpose: Certain clinicopathologic features correlate with BRAF mutation status in melanoma including younger age and primary subtype. This study sought to determine the by age-decade whether BRAF-mutant genotypes correlated outcome patients metastatic melanoma. Methods: A prospectively assembled cohort of Australian were followed from diagnosis (N = 308). Clinicopathologic variables mutational status, genotype, survival. Results: Forty-six percent had a mutation; 73% V600E, 19%...
Abstract BACKGROUND The current study was performed to determine whether tumor mitotic rate (TMR) is a useful, independent prognostic factor in patients with localized cutaneous melanoma. METHODS From the Sydney Melanoma Unit database, 3661 complete clinical information and details of primary thickness, ulcerative state, TMR were studied. expressed as mitoses per mm 2 dermal part which most seen, recommended 1982 revision 1972 classification malignant To more prognostically useful method...
To determine the survival rates and independent predictors of using a contemporary international cohort patients with stage III melanoma.